Constellation Pharmaceuticals (CNST) Issues Earnings Results

Constellation Pharmaceuticals (NASDAQ:CNST) issued its quarterly earnings results on Thursday. The company reported ($0.77) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.74) by ($0.03), Fidelity Earnings reports.

CNST traded up $0.11 on Friday, hitting $10.00. 18,491 shares of the company’s stock were exchanged, compared to its average volume of 61,866. Constellation Pharmaceuticals has a twelve month low of $4.01 and a twelve month high of $12.45.

Several analysts have recently issued reports on the stock. Zacks Investment Research cut shares of Constellation Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, March 5th. Robert W. Baird began coverage on shares of Constellation Pharmaceuticals in a research report on Monday, January 28th. They set an “outperform” rating and a $17.00 price target for the company. ValuEngine cut shares of Constellation Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, January 24th. Finally, HC Wainwright initiated coverage on shares of Constellation Pharmaceuticals in a research report on Thursday, December 20th. They set a “buy” rating and a $18.00 price target for the company. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $17.25.



A hedge fund recently raised its stake in Constellation Pharmaceuticals stock. Geode Capital Management LLC increased its holdings in shares of Constellation Pharmaceuticals Inc (NASDAQ:CNST) by 16.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 13,735 shares of the company’s stock after acquiring an additional 1,987 shares during the quarter. Geode Capital Management LLC owned approximately 0.05% of Constellation Pharmaceuticals worth $55,000 at the end of the most recent quarter. 60.05% of the stock is owned by institutional investors and hedge funds.

WARNING: “Constellation Pharmaceuticals (CNST) Issues Earnings Results” was posted by Dakota Financial News and is the property of of Dakota Financial News. If you are reading this report on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The original version of this report can be viewed at https://dakotafinancialnews.com/2019/03/15/constellation-pharmaceuticals-cnst-issues-earnings-results.html.

Constellation Pharmaceuticals Company Profile

Constellation Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidate CPI-1205 that is in Phase Ib/II clinical trials for the treatment of metastatic castration-resistant prostate cancer in combination with androgen receptor signaling inhibitors, as well as for the treatment of solid tumors in combination with immune checkpoint inhibitors.

See Also: Index Funds

Receive News & Ratings for Constellation Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Constellation Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply